Osiris Therapeutics, Inc.
News and overview for Osiris Therapeutics, Inc.
Osiris Therapeutics reports financial results for the third quarter of 2009
News-Medical.Net | 18 days 19 hours 10 minutes ago
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its financial results for the third quarter of 2009.
Osiris Therapeutics gets last Osteocel payment after NuVasive reports $35M in Osteocel revenue
Sun (Baltimore), The | 19 days 10 hours 10 minutes ago
Osiris Therapeutics Inc. said Tuesday it received a $15 million payment from NuVasive Inc., the final milestone fee linked to the sale of Osiris' bone graft stem cell business.
Osiris gets $15M milestone payment from NuVasive
Richmond Times-Dispatch (Va.) | 19 days 9 hours 48 minutes ago
NEW YORK (AP) -- Osiris Therapeutics Inc. said Tuesday it received a $15 million payment from NuVasive Inc., the final milestone fee linked to the sale of Osiris' bone graft stem cell business.
Osiris Therapeutics Reports Third Quarter 2009 Financial Results [Press Release]
Business Wire | 18 days 20 hours 27 minutes ago
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its financial results for the third quarter of 2009.
Osiris Therapeutics Achieves $15 Million Milestone Payment [Press Release]
Business Wire | 19 days 19 hours 57 minutes ago
Osiris Therapeutics, Inc. (NASDAQ: OSIR), today announced that the company has achieved a $15 million milestone payment from NuVasive (NASDAQ: NUVA) related to the sale of the Osteocel business. Triggering the payment, NuVasive recently reached $35 million in cumulative sales of Osteocel. With this final payment, Osiris has realized the full $85 million value from the sale of its Osteocel business to Nuvasive.
Osiris Therapeutics Announces Third Quarter 2009 Financial Results Conference Call [Press Release]
Business Wire | 30 days 19 hours 27 minutes ago
Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will report its financial results for the quarter ended September 30, 2009, on Wednesday, November 4, 2009. C. Randal Mills, Ph.D., President and Chief Executive Officer, and Philip R. Jacoby, Jr., Chief Financial Officer, will provide a company update and discuss results via a webcast and conference call on Wednesday, November 4, 2009 at 9:00 a.m. ET.
Research and Markets: An Essential Report on the Opportunities in Human Embryonic Stem Cell (hESCs) Products [Press Release]
Business Wire | 5 days 19 hours 56 minutes ago
Research and Markets (http://www.researchandmarkets.com/research/a39a10/opportunities_in_h) has announced the addition of the "Opportunities in Human Embryonic Stem Cell (hESCs) Products" report to their offering.
Osiris Therapeutics loses $6M in 3Q
American City Business Journals | 18 days 12 hours 2 minutes ago
Osiris Therapeutics Inc. lost $6.2 million in the third quarter despite growing revenue.
5th Annual Stem Cell Summit Set for Feb. 16 in New York City [Press Release]
PRNewswire | 60 days 16 hours 24 minutes ago
...South Street Seaport. Aastrom Biosciences, Inc. MaxCyte, Inc. AllCells, LLC Novocell, Inc. ArunA Biomedical, Inc. Osiris Therapeutics, Inc. Athersys, Inc. Pluristem Therapeutics Inc. BioE Inc. ProChon Biotech, Ltd. Cellerix...
Reportlinker Adds World Bone Grafts Market Report [Press Release]
PRNewswire | 73 days 17 hours 54 minutes ago
...Medtronic Sofamor Danek Inc., Musculoskeletal Transplant Foundation, NovaBone Products LLC, NuVasive Inc., Orthovita Inc., Osiris Therapeutics Inc., Osteotech Inc., RTI Biologics, Inc., Smith & Nephew Plc., Stryker Corporation, Synthes...
Research and Markets: Cord Blood Stem Cells - This Global Market Overview [Press Release]
Business Wire | 24 days 20 hours 19 minutes ago
Research and Markets (http://www.researchandmarkets.com/research/b55293/cord_blood_stem_ce) has announced the addition of the "Cord Blood Stem Cells - A Global Market Overview" report to their offering.
Reportlinker Adds Global Stem Cell and Advanced Technologies Market [Press Release]
PRNewswire | 12 days 11 hours 49 minutes ago
NEW YORK, Nov. 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.
MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 [Press Release]
PRNewswire | 19 days 16 hours 57 minutes ago
WILMINGTON, Delaware, November 3 /PRNewswire/ -- The new market research report, 'Global Stem Cell and Advanced Technologies Market' (2009 - 2014)', published by MarketsandMarkets (
US HOT STOCKS: Charles River Active In Late Trading
Wall Street Journal, The | 19 days 9 hours 23 minutes ago
U.S. stocks closed mixed Tuesday as the Dow Jones Industrial Average lost 18 points to 9772, the S&P 500 rose 3 points to 1045 and the Nasdaq Composite gained 8 points to 2057. Among the companies whose shares are actively trading in the after-hours session are Charles River Laboratories International Inc. (CRL), Hartford Financial Services Group Inc. (HIG) and Kraft Foods Inc. (KFT).
US HOT STOCKS: Burlington Northern, Black & Decker
Wall Street Journal, The | 19 days 12 hours 18 minutes ago
U.S. stocks were mixed Tuesday as the Dow Jones Industrial Average fell 13 points to 9777, but the S&P 500 edged up 2 points to 1045 and the Nasdaq Composite increased 2 points to 2051. Among the companies whose shares are actively trading in Tuesday's session are Burlington Northern Santa Fe Corp. (BNI), Black & Decker Corp. (BDK) and Sonic Solutions (SNIC).
Sign up for ANA SmartBrief
Company Overview
| Company: | Osiris Therapeutics, Inc. |
|---|---|
| Industry: | Biopharmaceuticals & Biotherapeutics |
| Website: | http://www.osiristx.com |
Osiris Therapeutics works at the cellular level. The company develops products aimed at treating cardiovascular, inflammatory, and orthopedic disorders. Its lead drug candidate, Prochymal, is in clinical trials to be used by those with Crohn's disease and diabetes, as well as to repair tissue in heart attack and pulmonary disease patients. Another drug candidate, Chondrogen, is under evaluation to treat osteoarthritis in the knee. Osiris has partnered with Genzyme to develop and commercialize both Prochymal and Chondrogen; the two companies are also exploring Prochymal as a possible medical countermeasure to nuclear terrorism. Chairman Peter Friedli holds about 48% of the company's stock.
Key Numbers
| Sales in U.S. Dollars (mil.) | 10 (2008) |
|---|---|
| One-year % Growth in Sales | -34.1 (2008) |
| Net Income in U.S. Dollars (mil.) | -33.5 (2008) |
| One-year % Growth in Net Income | 0.0 (2008) |
| Number of Employees | 163 (2008) |
| One-year % Growth in Number of Employees | 22.6 (2008) |
| Fiscal Year-End | December |